The Genomic Investigation of Statin Therapy (GIST) consortium comprises both randomized controlled trials and observational studies, which collaborate to perform large-scale genome-wide association studies to identify genetic factors of importance to statin response. From the LUMC the PROSPER/PHASE study contributes to these projects, which include data of more than 25,000 statin-treated individuals.
Statins are amongst the most successful therapeutic interventions to lower cardiovascular risk. However, there exists large interindividual variation with regard to statin response, in part due to genetic factors. The GIST consortium aims to discover which genetic variation is responsible for the variation in response to statin therapy, which may help to tailor lipid-modifying therapy in clinical settings.
For more information on the GIST consortium please contact Stella Trompet (email@example.com).